Clinical trial
HORIZON-PFT: Pivotal Fracture Trial
NCT00049829 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00049829 |
|---|---|
| Title | HORIZON-PFT: Pivotal Fracture Trial |
| Official title | HORIZON-PFT: Pivotal Fracture Trial |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | Zoledronic Acid |
| Enrollment | 7,700 |
| Start date | Jan 1, 2002 |
| Primary completion | Jun 1, 2006 |
| First posted | Nov 15, 2002 |
| Last update posted | Nov 2, 2011 |
| Countries | Germany, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: